Table 3

The risk of outcomes stratified by COVID-19 vaccination status

Outcomes	With vaccination*
	Patients with outcome		HR (95% CI)††	Patients with outcome		HR (95% CI)††
	JAKi	TNFi	HR (95% CI)††	IL-6i	TNFi	HR (95% CI)††
Total, N	444	444		161	161
Disease incidence
COVID-19	64	79	1.005 (0.722 to 1.400)	28	38	0.738 (0.452 to 1.204)
Medical utilisation
Hospitalisation	53	51	1.260 (0.856 to 1.855)	25	18	1.322 (0.721 to 2.425)
Critical care services	15	13	1.368 (0.649 to 2.800)	10	10	0.505 (0.126 to 2.020)
Mechanical ventilation	10	10	1.152 (0.287 to 4.622)	10	10	1.561 (0.261 to 9.350)
Mortality
Deceased	10	10	2.128 (0.752 to 6.023)	10	10	2.498 (0.484 to 12.88)
Adverse outcomes‡‡	55	53	1.272 (0.870 to 1.860)	26	18	1.377 (0.754 to 2.512)
	Without vaccination§§
Total, N	2224	2224		802	802
Disease incidence
COVID-19	201	210	1.113 (0.917 to 1.352)	71	78	1.015 (0.736 to 1.400)
Medical utilisation
Hospitalisation	206	210	1.082 (0.892 to 1.312)	77	72	1.154 (0.837 to 1.592)
Critical care services	54	51	1.174 (0.800 to 1.722)	17	20	0.909 (0.476 to 1.735)
Mechanical ventilation	32	25	1.429 (0.846 to 2.414)	10	10	1.062 (0.398 to 2.829)
Mortality
Deceased	78	59	1.511 (1.077 to 2.121)	25	32	0.854 (0.506 to 1.441)
Adverse outcomes‡‡	235	232	1.127 (0.940 to 1.352)	84	84	1.083 (0.800 to 1.466)

Note: If the patient number is less than or equal to 10, the results show the count as 10.
Bold font indicates statistical significance.
*Subjects who were ever vaccinated with COVID-19-related vaccines documented in their health record.
†Patients in each cohort were matched for age at index, sex, race, socioeconomic status, lifestyles, comorbidities, medical utilisation, COVID-19 vaccination status and medication usage.
‡Including hospitalisation, critical care services, mechanical ventilation or deceased.
§Subjects who were never vaccinated with COVID-19-related vaccines documented in their health record.
IL-6i, interleukin 6 inhibitors; JAKi, Janus-associated kinase inhibitors; TNFi, tumour necrosis factor alpha inhibitors.